Nifty Pharma PB	4.9
Nifty Pharma PE	32.9
Nifty Pharma DIV	0.7
Nifty Pharma EPS	689.4

Nifty Pharma News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Nifty Pharma from all sources in a single place.

Biocon Ltd.

19 Sep 2025, 08:43PM

369.20

0.22%

Company Update

Biocon Ltd - 532523 - Buyback Of Commercial Paper

BSE India

Buyback of Commercial Paper

pdf

Ajanta Pharma Ltd.

19 Sep 2025, 07:39PM

2544.60

-0.15%

Broker's call: Ajanta Pharma (Buy)

Business Line

PL Capital

Ajanta Pharma Ltd. has an average target of 3022.00 from 5 brokers.

Aurobindo Pharma Ltd.

19 Sep 2025, 03:17PM

1119.20

-0.86%

Fire at Aurobindo Pharma's subsidiary unit in AP

Business Line

Mishap at APL healthcare's Naidupeta in AP caused temporary disruption of produciton

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.

Aurobindo Pharma Ltd.

19 Sep 2025, 01:24PM

1119.20

-0.86%

Company Update

Aurobindo Pharma Ltd - 524804 - Fire Accident At Unit-IV Of APL Healthcare Limited, A Wholly …

BSE India

Intimation of fire accident at Unit 4 of APL Healthcare Limited, a wholly owned subsidiary of the Company.

pdf

Laurus Labs Ltd.

19 Sep 2025, 12:53PM

932.10

0.96%

Laurus Labs soars 6% in 2 days, market cap tops 50,000 crore; here's why

Business Standard

At 11:29 AM, Laurus Labs' stock was quoting 2 per cent higher at 943.15 on the BSE, commanding an m-cap of 50,913 crore, exchange data shows

Laurus Labs Ltd. is trading at high day volume of 3.4M.

Dr. Reddy's Laboratories Ltd.

19 Sep 2025, 11:02AM

1321.70

-0.08%

SAST

Dr Reddys Laboratories Ltd - 500124 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for VSD Family Trust & PACs

pdf

Dr. Reddy's Laboratories Ltd.

19 Sep 2025, 10:59AM

1321.70

-0.08%

SAST

Dr Reddys Laboratories Ltd - 500124 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for VSD Family Trust & PACs

pdf

Natco Pharma Ltd.

19 Sep 2025, 10:53AM

884.25

-0.01%

SAST

Natco Pharma Ltd - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Satya Vani Nannapaneni

pdf

Glenmark Pharmaceuticals Ltd.

19 Sep 2025, 10:29AM

2085.20

-1.10%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

Kindly find enclosed rating rationale issued by CRISIL Ratings for your reference.

pdf

Aurobindo Pharma Ltd.

19 Sep 2025, 10:19AM

1119.20

-0.86%

Company Update

Aurobindo Pharma Ltd - 524804 - Curateq Biologics Announces Successful Completion Of Phase 3 Clinical Study …

BSE India

Submission of disclosure of successful of phase 3 clinical study for Denosumab Biosimilar by CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company.

pdf

Is Nifty Pharma worth buying?

324 Votes:

Buy 79.32%

Sell 11.73%

Hold 8.95%